Novel HER2 Drug Shrinks Lung Cancer Tumors in Early Trial

(MedPage Today) — BERLIN — An investigational oral drug currently under review with the FDA showed durable antitumor activity in patients with HER2-mutant advanced non-small cell lung cancer (NSCLC), findings from an international phase I/II…

Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118084

Author :

Publish date : 2025-10-22 17:31:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

Novel HER2 Drug Shrinks Lung Cancer Tumors in Early Trial

Could This Be the First Disease-Modifying Drug in Bronchiectasis?

Over 25% of Ocular Complications From Dupilumab in Kids Developed After a Year

Related Posts

‘Weaponised’ CAR T-cell therapy shows promise against solid tumours

NHS health checks to include questions about the menopause

I thought my insides were falling out – what I didn’t expect after childbirth

Bad Gums Tied to Big Brain Risks

Novel T-Cell Therapy Promising in Tough-to-Treat Eye Cancer

‘Alternative’ to CDC’s Flagship Journal in the Works

‘Weaponised’ CAR T-cell therapy shows promise against solid tumours

NHS health checks to include questions about the menopause

I thought my insides were falling out – what I didn’t expect after childbirth

Bad Gums Tied to Big Brain Risks

Novel T-Cell Therapy Promising in Tough-to-Treat Eye Cancer

‘Alternative’ to CDC’s Flagship Journal in the Works

Can Steroids Be Stopped in Lupus Nephritis? Yes, and Here’s How

A Peek Inside the Blue Medical Tent That Has Become a Fixture on NFL Sidelines

Categories

Archives